ReviewInternational journal of biological sciences2012
Immunotherapies: the blockade of inhibitory signals.
Review in International journal of biological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Negative Immune Checkpoint Inhibitors.Pharmaceutics · 2025Review
- Differential expression of circulating miRNAs after alemtuzumab induction therapy in lung transplantation.Scientific reports · 2022Article
- B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.International journal of biological sciences · 2020Review
- Vessel pruning or healing: endothelial metabolism as a novel target?Expert opinion on therapeutic targets · 2017Review
- Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways.Scientific reports · 2016Article
- Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.Journal of neuroinflammation · 2016Article
- Non-small cell lung cancer: current treatment and future advances.Translational lung cancer research · 2016Review
- Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage.Journal of immunology research · 2015Review
- Immunotherapeutic strategies in autoimmune uveitis.Autoimmunity reviews · 2014Review
- Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.PloS one · 2014Article
- Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.PloS one · 2014Article
- Novel immunotherapies in GU malignancies.Current oncology reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T lymphocytes require signaling by the T cell receptor and by nonclonotypic cosignaling receptors. The costimulatory and inhibitory signals profoundly influence the course of immune responses by amplifying or reducing the transcriptional effects of T cell receptor triggering. The inhibitory receptors such as CTLA-4, PD-1, and BTLA have recently drawn much attention as potential targets for immunotherapies. This review focuses on the progress that has been made with the mentioned receptors in the field of immunotherapies for autoimmune diseases, malignancies, infectious diseases, and transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.